JP2014516516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516516A5 JP2014516516A5 JP2014508166A JP2014508166A JP2014516516A5 JP 2014516516 A5 JP2014516516 A5 JP 2014516516A5 JP 2014508166 A JP2014508166 A JP 2014508166A JP 2014508166 A JP2014508166 A JP 2014508166A JP 2014516516 A5 JP2014516516 A5 JP 2014516516A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- wing segment
- modified oligonucleotide
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 40
- 239000002777 nucleoside Substances 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 15
- 241001465754 Metazoa Species 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000003835 nucleoside group Chemical group 0.000 claims 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 230000000291 postprandial effect Effects 0.000 claims 6
- 108010004103 Chylomicrons Proteins 0.000 claims 5
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 206010033645 Pancreatitis Diseases 0.000 claims 4
- 229940104302 cytosine Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 2
- 101001094647 Homo sapiens Serum paraoxonase/arylesterase 1 Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 102100035476 Serum paraoxonase/arylesterase 1 Human genes 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims 2
- 230000009395 genetic defect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229960004042 diazoxide Drugs 0.000 claims 1
- -1 diazoxide salt Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 229940127208 glucose-lowering drug Drugs 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479817P | 2011-04-27 | 2011-04-27 | |
| US61/479,817 | 2011-04-27 | ||
| US201261595009P | 2012-02-03 | 2012-02-03 | |
| US61/595,009 | 2012-02-03 | ||
| PCT/US2012/035694 WO2012149495A1 (en) | 2011-04-27 | 2012-04-27 | Modulation of apolipoprotein ciii (apociii) expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138210A Division JP2017008059A (ja) | 2011-04-27 | 2016-07-13 | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516516A JP2014516516A (ja) | 2014-07-17 |
| JP2014516516A5 true JP2014516516A5 (OSRAM) | 2014-12-25 |
| JP6203707B2 JP6203707B2 (ja) | 2017-09-27 |
Family
ID=47072800
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508166A Active JP6203707B2 (ja) | 2011-04-27 | 2012-04-27 | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 |
| JP2016138210A Pending JP2017008059A (ja) | 2011-04-27 | 2016-07-13 | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 |
| JP2018128233A Pending JP2018168184A (ja) | 2011-04-27 | 2018-07-05 | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138210A Pending JP2017008059A (ja) | 2011-04-27 | 2016-07-13 | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 |
| JP2018128233A Pending JP2018168184A (ja) | 2011-04-27 | 2018-07-05 | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9157082B2 (OSRAM) |
| EP (2) | EP3357497B1 (OSRAM) |
| JP (3) | JP6203707B2 (OSRAM) |
| KR (3) | KR20190062511A (OSRAM) |
| CN (3) | CN107714715A (OSRAM) |
| AU (3) | AU2012249324B2 (OSRAM) |
| BR (1) | BR112013027479A8 (OSRAM) |
| CA (1) | CA2834232A1 (OSRAM) |
| DK (2) | DK2701713T3 (OSRAM) |
| ES (2) | ES2663635T3 (OSRAM) |
| IL (1) | IL229010A0 (OSRAM) |
| MY (1) | MY162715A (OSRAM) |
| NZ (1) | NZ710192A (OSRAM) |
| RU (2) | RU2603076C9 (OSRAM) |
| SG (2) | SG10201606174RA (OSRAM) |
| UA (1) | UA115309C2 (OSRAM) |
| WO (1) | WO2012149495A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2632967T3 (es) | 2008-09-02 | 2017-09-18 | Amarin Pharmaceuticals Ireland Limited | Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma |
| LT2424356T (lt) | 2009-04-29 | 2017-11-27 | Amarin Pharmaceuticals Ireland Limited | Stabili farmacinė kompozicija ir jos panaudojimo būdai |
| NZ807894A (en) | 2009-04-29 | 2025-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| KR102012111B1 (ko) | 2009-06-15 | 2019-08-19 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| UA115309C2 (uk) | 2011-04-27 | 2017-10-25 | Іоніс Фармасьютікалз, Інк. | Модуляція експресії аполіпопротеїну ciii (apociii) |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| JPWO2013089157A1 (ja) * | 2011-12-12 | 2015-04-27 | 独立行政法人国立循環器病研究センター | オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する高脂血症治療剤 |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| CN104582698A (zh) | 2012-06-29 | 2015-04-29 | 阿玛林制药爱尔兰有限公司 | 在接受抑制素治疗的受试者中降低心血管事件风险的方法 |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| DK2956176T3 (en) * | 2013-02-14 | 2018-08-27 | Ionis Pharmaceuticals Inc | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9783600B2 (en) | 2013-02-25 | 2017-10-10 | Imbp Holding, Llc | Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL) |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| BR112015027322A8 (pt) | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | Compostos antissenso conjugados e sua utilização |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20160122761A1 (en) | 2013-06-21 | 2016-05-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| US9909124B2 (en) | 2013-06-21 | 2018-03-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile |
| US20150045431A1 (en) * | 2013-08-06 | 2015-02-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| EP3845547A1 (en) | 2014-05-01 | 2021-07-07 | Ionis Pharmaceuticals, Inc. | Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| WO2016069446A1 (en) * | 2014-10-28 | 2016-05-06 | Omthera Pharmaceuticals Inc | Methods for modulating plasma levels of lipoproteins |
| KR20170122769A (ko) * | 2015-02-27 | 2017-11-06 | 아이오니스 파마수티컬즈, 인코포레이티드 | 지방이상증 집단에서 아포지단백질 C-III (ApoCIII) 발현의 조절 |
| PT4119569T (pt) | 2015-11-06 | 2024-10-23 | Ionis Pharmaceuticals Inc | Compostos antissentido conjugados para utilização em terapia |
| CN113952353A (zh) | 2015-11-06 | 2022-01-21 | Ionis制药公司 | 调节载脂蛋白(a)表达 |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| CN108239644B (zh) * | 2016-12-23 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| WO2018223056A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN118291456A (zh) * | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3718572B1 (en) | 2017-12-01 | 2024-07-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
| EP3719128B1 (en) | 2017-12-01 | 2025-01-15 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
| JP7436030B2 (ja) | 2017-12-29 | 2024-02-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 複合体及びその調製方法と使用 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| AU2019265904A1 (en) | 2018-05-11 | 2020-11-12 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| KR20230038594A (ko) | 2018-09-24 | 2023-03-20 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN118256498A (zh) | 2019-05-22 | 2024-06-28 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP4058141A4 (en) | 2019-11-12 | 2023-11-22 | Amarin Pharmaceuticals Ireland Limited | METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114934074A (zh) * | 2022-06-01 | 2022-08-23 | 北京大学 | 一种ApoC3基因敲除仓鼠模型的构建方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| JPH02242158A (ja) * | 1989-03-15 | 1990-09-26 | Nippon Shoji Kk | ヒトアポリポ蛋白ｃ―３の測定法 |
| US6852536B2 (en) | 2001-12-18 | 2005-02-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD36L 1 expression |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| WO1992010590A1 (en) | 1990-12-10 | 1992-06-25 | Gilead Sciences, Inc. | Inhibition of transcription by formation of triple helixes |
| AU665939B2 (en) | 1990-12-21 | 1996-01-25 | Rockefeller University, The | Liver enriched transcription factor |
| US5578444A (en) | 1991-06-27 | 1996-11-26 | Genelabs Technologies, Inc. | Sequence-directed DNA-binding molecules compositions and methods |
| US5877009A (en) | 1991-08-16 | 1999-03-02 | Trustees Of Boston University | Isolated ApoA-I gene regulatory sequence elements |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| IT1277025B1 (it) | 1995-12-04 | 1997-11-04 | Cooperativa Centro Ricerche Po | Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
| GB0121171D0 (en) * | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1499627A2 (en) | 2001-07-03 | 2005-01-26 | ISIS Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP2957568B1 (en) | 2002-11-05 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| WO2004085996A2 (en) * | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| US7750142B2 (en) * | 2003-04-28 | 2010-07-06 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| DK1623228T3 (da) | 2003-04-29 | 2013-01-14 | Biocrine Ab | Aopciii og behandling og diagnose af diabetes |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
| EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| WO2010083615A1 (en) | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
| WO2010107838A1 (en) * | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
| US8668937B2 (en) * | 2011-03-17 | 2014-03-11 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
| UA115309C2 (uk) * | 2011-04-27 | 2017-10-25 | Іоніс Фармасьютікалз, Інк. | Модуляція експресії аполіпопротеїну ciii (apociii) |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| DK2956176T3 (en) * | 2013-02-14 | 2018-08-27 | Ionis Pharmaceuticals Inc | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2012
- 2012-04-27 UA UAA201313754A patent/UA115309C2/uk unknown
- 2012-04-27 CN CN201711012874.9A patent/CN107714715A/zh active Pending
- 2012-04-27 DK DK12776385.2T patent/DK2701713T3/en active
- 2012-04-27 ES ES12776385.2T patent/ES2663635T3/es active Active
- 2012-04-27 RU RU2013153147A patent/RU2603076C9/ru active
- 2012-04-27 AU AU2012249324A patent/AU2012249324B2/en active Active
- 2012-04-27 CN CN201280024206.7A patent/CN103547271A/zh active Pending
- 2012-04-27 SG SG10201606174RA patent/SG10201606174RA/en unknown
- 2012-04-27 US US14/114,187 patent/US9157082B2/en active Active
- 2012-04-27 RU RU2016138742A patent/RU2016138742A/ru not_active Application Discontinuation
- 2012-04-27 NZ NZ710192A patent/NZ710192A/en unknown
- 2012-04-27 ES ES18155337T patent/ES2833468T3/es active Active
- 2012-04-27 EP EP18155337.1A patent/EP3357497B1/en active Active
- 2012-04-27 KR KR1020197012680A patent/KR20190062511A/ko not_active Ceased
- 2012-04-27 MY MYPI2013702025A patent/MY162715A/en unknown
- 2012-04-27 EP EP12776385.2A patent/EP2701713B1/en not_active Revoked
- 2012-04-27 JP JP2014508166A patent/JP6203707B2/ja active Active
- 2012-04-27 KR KR1020177033202A patent/KR102021688B1/ko active Active
- 2012-04-27 CA CA2834232A patent/CA2834232A1/en not_active Abandoned
- 2012-04-27 DK DK18155337.1T patent/DK3357497T3/da active
- 2012-04-27 BR BR112013027479A patent/BR112013027479A8/pt not_active Application Discontinuation
- 2012-04-27 SG SG2013079959A patent/SG194671A1/en unknown
- 2012-04-27 WO PCT/US2012/035694 patent/WO2012149495A1/en not_active Ceased
- 2012-04-27 CN CN201711012872.XA patent/CN107854478A/zh active Pending
- 2012-04-27 KR KR1020137030993A patent/KR101800333B1/ko active Active
-
2013
- 2013-10-21 IL IL229010A patent/IL229010A0/en unknown
-
2015
- 2015-08-07 US US14/821,641 patent/US20160060625A1/en not_active Abandoned
-
2016
- 2016-07-13 JP JP2016138210A patent/JP2017008059A/ja active Pending
-
2017
- 2017-01-04 AU AU2017200025A patent/AU2017200025B2/en active Active
- 2017-05-25 US US15/605,579 patent/US20170268004A1/en not_active Abandoned
-
2018
- 2018-07-05 JP JP2018128233A patent/JP2018168184A/ja active Pending
-
2019
- 2019-02-13 AU AU2019201011A patent/AU2019201011A1/en not_active Abandoned
- 2019-05-28 US US16/424,100 patent/US20200056176A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516516A5 (OSRAM) | ||
| JP2016513110A5 (OSRAM) | ||
| RU2016138742A (ru) | МОДУЛИРОВАНИЕ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА СIII (АроСIII) | |
| RU2015151200A (ru) | Композиции и способы модулирования экспрессии аполипопротеина (а) | |
| Xie et al. | Therapy of cancer metastasis by activation of the inducible nitric oxide synthase | |
| Lü et al. | Homoharringtonine and omacetaxine for myeloid hematological malignancies | |
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| ES2863929T3 (es) | Fenfluramina para uso en el tratamiento de síndrome de Dravet | |
| RU2016146817A (ru) | Композиции и способы модулирования экспрессии ангиопоэтин-подобного белка 3 | |
| JP2018126141A5 (OSRAM) | ||
| JP2009542702A5 (OSRAM) | ||
| JP2016522817A5 (OSRAM) | ||
| JP2018535989A5 (OSRAM) | ||
| JP2011528333A5 (OSRAM) | ||
| JP2011516410A5 (OSRAM) | ||
| JP2014511686A5 (OSRAM) | ||
| JP2009542699A5 (OSRAM) | ||
| JP2005520778A5 (OSRAM) | ||
| Abbate | The heart on fire: inflammasome and cardiomyopathy. | |
| JP2014504857A5 (OSRAM) | ||
| JP2014526492A5 (OSRAM) | ||
| JP2014521310A5 (OSRAM) | ||
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| Shukla et al. | Novel non-biologic targets for inflammatory bowel disease | |
| RU2015120365A (ru) | Ингибирующие олигонуклеотиды и их применение |